v3.26.1
Stock Based Compensation
3 Months Ended
Jun. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Stock Based Compensation

Note 10 - STOCK BASED COMPENSATION

ESOP

Employees participate in an Employee Stock Ownership Plan ("ESOP"). The ESOP borrowed funds from the Company to purchase 330,465 shares of stock at $10 per share. The Association makes discretionary contributions to the ESOP and the ESOP uses funds it receives to repay the loan. When loan payments are made, ESOP shares are allocated to participants based on relative compensation. Participants receive the shares at the end of employment.

There were no contributions to the ESOP during the three months ended June 30, 2026 and 2025, as the annual loan payment is made in December. The ESOP compensation expense for three months ended June 30, 2026 and 2025 was $59,000 and $49,000, respectively.

Shares held by the ESOP were as follows:

 

 

 

As of June 30,

 

 

 

2026

 

 

2025

 

 

 

(Dollars in thousands)

 

Shares allocated

 

 

46,272

 

 

 

33,048

 

Unallocated

 

 

284,193

 

 

 

297,417

 

Total ESOP shares

 

 

330,465

 

 

 

330,465

 

Fair value of unearned shares as of June 30, 2026 and 2025, respectively

 

$

5,408

 

 

$

4,497

 

 

Fair value of unearned shares is based on a stock price of $19.03 and $15.12 as of June 30, 2026 and 2025, respectively.

Equity Incentive plan

At the Company's annual meeting of stockholders held on November 26, 2024, stockholders approved the Central Plains Bancshares, Inc. 2024 Equity Incentive Plan (“2024 Equity Plan”), which provides for the granting of up to 578,313 shares (165,232 shares of restricted stock and 413,081 stock options) of the Company’s common stock pursuant to equity awards made under the 2024 Equity Plan.

Stock options granted under the 2024 Equity Plan generally vest in equal annual installments over a service period of five years beginning one year from the date of grant. The vesting of the options accelerates upon death, disability or an involuntary termination at or following a change in control of the Company. Stock options are generally granted at an exercise price equal to the fair value of the Company’s common stock on the grant date based on the closing market price of the Company's common stock on the date of grant, and have an expiration period of ten years. As of June 30, 2026, the Company has 93,157 stock options available for future grants under the 2024 Equity Plan.

The Company recognizes compensation expense for the fair values of these awards, which have graded vesting, on a straight-line basis over the requisite service period of the awards. Upon exercise of vested options, management expects to first draw on retired stock as the source for shares.

The following is a summary of the Company's stock option activity and related information for the periods presented.

 

Stock Options - for the three months ended June 30, 2026 and 2025

 

Shares

 

 

Weighted Average Exercise Price

 

 

Weighted Average Remaining Contractual Term (in years)

 

 

Aggregate Intrinsic Value

 

 

 

 

 

 

 

 

 

 

(Dollars in thousands)

 

Options, outstanding at March 31, 2026

 

 

319,924

 

 

$

14.63

 

 

 

8.8

 

 

 

 

Granted

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

1,000

 

 

 

 

 

 

 

 

 

 

Forfeited

 

 

 

 

 

 

 

 

 

 

 

 

Options, outstanding at June 30, 2026

 

 

318,924

 

 

$

14.63

 

 

 

8.5

 

 

 

1,408

 

Exercisable - End of Period

 

 

64,785

 

 

 

 

 

 

 

 

$

285

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options, outstanding at March 31, 2025

 

 

308,924

 

 

$

14.63

 

 

 

9.7

 

 

 

 

Granted

 

 

15,000

 

 

 

14.61

 

 

 

9.9

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

Forfeited

 

 

 

 

 

 

 

 

 

 

 

 

Options, outstanding at June 30, 2025

 

 

323,924

 

 

$

14.63

 

 

 

9.5

 

 

 

159

 

Exercisable - End of Period

 

 

 

 

 

 

 

 

 

 

$

 

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value, the difference between the Company's closing stock price on the last trading day of the period and the exercise price, multiplied by the number of in-the-money options.

Expected future expense relating to the non-vested options outstanding as of June 30, 2026, is $1.3 million over a weighted average period of 3.5 years.

Restricted shares granted under the 2024 Equity Plan generally vest in equal annual installments over a service period of five years beginning one year from the date of grant. The vesting of the awards accelerates upon death, disability or an involuntary termination at or following a change in control of the Company. The product of the number of shares granted and the grant date closing market price of the Company’s common stock determines the fair value of restricted shares under the 2024 Equity Plan. Management recognizes compensation expense for the fair value of restricted shares on a straight-line basis over the requisite service period.

As of June 30, 2026, the Company has 28,367 shares of restricted stock available for future grants under the 2024 Equity Plan.

The following is a summary of the status of the Company's restricted shares as of and for the periods presented.

 

Restricted Stock - for the three months ended June 30, 2026 and 2025

 

Shares

 

 

Weighted Average Grant Date Fair Value

 

 

 

 

 

 

Nonvested balance as of March 31, 2026

 

 

111,054

 

 

$

14.64

 

Granted

 

 

 

 

 

 

Vested

 

 

(1,800

)

 

 

14.61

 

Forfeited

 

 

 

 

 

 

Nonvested balance as of June 30, 2026

 

 

109,254

 

 

$

14.64

 

 

 

 

 

 

 

 

Nonvested balance as of March 31, 2025

 

 

129,066

 

 

$

14.64

 

Granted

 

 

9,000

 

 

 

14.61

 

Vested

 

 

 

 

 

 

Forfeited

 

 

 

 

 

 

Nonvested balance as of June 30, 2025

 

 

138,066

 

 

$

14.64

 

Expected future expense relating to the non-vested restricted shares outstanding as of June 30, 2026, is $1.4 million over a weighted average period of 3.5 years.

The following table presents the stock-based compensation expense for the periods presented.

 

 

 

For the Three Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

 

(Dollars in thousands)

 

Stock option expense

 

$

90

 

 

$

88

 

Restricted stock expense

 

 

99

 

 

 

97

 

   Total stock-based compensation expense

 

$

189

 

 

$

185